Results of a Phase II Study of Palbociclib in Esophageal and Gastric Cancer
Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced <br /> esophageal or gastric cancer.<br />
Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced
esophageal or gastric cancer.
The efficacy was not particularly notable among the 21 patients on this study, Karasic notes. Five of the patients achieved stable disease for greater than 2 months and 2 of the patients achieved stable disease for greater than 4 months. The patient with the longest duration of response was the only patient who continued trastuzumab (Herceptin) on study.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
